アトピー性皮膚炎患者における全身性コルチコステロイド暴露:米国の人口ベースの研究
Christopher G Bunick1, Ruth Ann Vleugels2, Mark Lebwohl3
1Department of Dermatology and Program in Translational Biomedicine, Yale School of Medicine, New Haven, CT, USA.
Dermatology and therapy
|February 22, 2026
まとめ
全身性コルチコステロイドは,ガイドラインが推奨しないにもかかわらず,米国ではアトピー性皮膚炎 (AD) に広く使用されています. これは,ステロイド依存を減らすための代替治療法の必要性を強調しています.
科学分野:
- 皮膚科 皮膚科について
- 薬理学 薬理学とは
- 現実世界の証拠の研究は,現実世界の証拠の研究です.
背景:
- 臨床ガイドラインは,副作用のために,アトピー性皮膚炎 (AD) のための日常的な全身コルチコステロイドの使用を推奨していません.
- これらの勧告を現実の世界で遵守することは,よく理解されていません.
研究 の 目的:
- アトピー性皮膚炎 (AD) と診断された患者の全身性コルチコステロイド処方に関するガイドラインの実際の使用と遵守を評価する.
主な方法:
- 米国の医療保険請求データを分析した遡及的なコホート研究 (Optum Clinformatics Data Mart Database).
- 2つのコホートが確立されました:被曝コホート (AD後の最初の全身性コルチコステロイド使用診断) と診断に基づくコホート (ADの最初の診断).
- 2017年から2024年の間にADを患った12歳以上の患者および継続的な保険が含まれており,他の炎症性疾患または重大な病歴に関する特定の除外基準が設けられました.
主要な成果:
- 暴露コホート (29,994人の患者) の67.7%が短期,8.5%が中期,そして23.9%が長期の全身性コルチコステロイド療法を受けた.
- 口服用全身用コルチコステロイドは処方薬の80.0%を占め,肌内処方薬は20.0%を占めた.
- 診断に基づくコホート (80,647人の患者) は,AD診断から6ヶ月以内に全身性コルチコステロイド使用の20.0%の流行を示しました.
結論:
- 米国では,全身性コルチコステロイドは,アトピー性皮膚炎 (AD) の患者に頻繁に処方されています.
- 現在の処方パターンは,日常的な使用を推奨しない臨床ガイドラインの遵守が限られていることを示しています.
- ADの管理のためにコルチコステロイドを節約する治療法の採用を促進する重要な必要性があります.
関連する概念動画
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.7K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.7K
Drug Toxicity: Allergic Reactions
39
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
39
Allergic Drug Reactions
1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Allergic Reactions
32.6K
Overview
32.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
565
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
565


